Synonyms: PBF509
Compound class:
Synthetic organic
Comment: PBF-509 is an adenosine A2A receptor antagonist that is being developed by Palobiofarma [2-3]. It is being considered for clinical potential as an immuno-onclogy adjunctive agent and as a treatment for movement disorder in Parkinson's disease patients. Although the chemical structure of PBF-509 has not been formally disclosed, a comparision of published data and Palobiofarma patent documents leads us to consider Example 1 from WO2011121418A1 [1] as a likely candidate for this antagonist (binding and functional data values in the patent match data published in the peer reviewed articles that describe PBF-509). We await full disclosure to be certain of our decision.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|